Tag Archives: United States

Pompeo voices confidence U.S. vote count will lead to ‘second Trump administration’

By Humeyra Pamuk

WASHINGTON (Reuters) – U.S. Secretary of State Mike Pompeo on Tuesday voiced confidence that once every “legal” vote was counted, it would lead to a “second Trump administration,” appearing to reject Democratic challenger Joe Biden’s victory over President Donald Trump.

He spoke as world leaders, including Washington’s close allies Britain and France, already have congratulated President-elect Biden. Trump, a Republican, has so far refused to concede and made baseless claims that fraud was marring the results.

“There will be a smooth transition to a second Trump administration,” Pompeo told a State Department news conference. He later sought to assure the world that America’s post-election transition would be successful.

“We’re going to count all the votes … The world should have every confidence that the transition necessary to make sure that the State Department is … successful today and successful when the president who’s in office on January 20, a minute after noon, will also be successful.”

Biden, due to take office on Jan. 20, 2021, risks a delayed transition as Trump has vowed to push ahead with longshot legal challenges to his election loss. Republican U.S. lawmakers have defended his right to do so.

Asked if Trump’s refusal to concede hampers State Department efforts to promote free and fair elections abroad, Pompeo, a close ally and appointee of Trump’s, said: “This department cares deeply to make sure that elections around the world are safe and secure and free and fair.”

The leading Republican in Congress, Senate Majority Leader Mitch McConnell, has carefully backed Trump, saying that he was “100% within his rights to look into allegations of irregularities,” without citing any evidence.

And U.S. Attorney General William Barr, a Trump appointee who heads the Justice Department, on Monday told federal prosecutors to “pursue substantial allegations” of irregularities of voting and the counting of ballots.

In his first official travel after the Nov. 3 election, Pompeo is due to travel to France, Turkey, Georgia, Israel, Qatar, United Arab Emirates and Saudi Arabia between Nov. 13-23. The leaders of some of those countries have already congratulated Biden.

(Reporting by Humeyra Pamuk Susan Heavey and David Brunnstrom; Editing by Howard Goller)

U.S. approves $23.37 billion advanced arms sale to UAE, Pompeo says

By Matt Spetalnick and Pete Schroeder

WASHINGTON (Reuters) – The Trump administration told Congress on Tuesday it had approved the U.S. sale of more than $23 billion in advanced weapons systems, including F-35 fighter jets and armed drones, to the United Arab Emirates, Secretary of State Mike Pompeo said.

The formal notification followed a U.S.-brokered agreement in September in which the UAE agreed to normalize relations with Israel, becoming the first of three Arab states to make such a move in recent months.

“This is in recognition of our deepening relationship and the UAE’s need for advanced defense capabilities to deter and defend itself against heightened threats from Iran,” Pompeo said in a statement.

The $23.37 billion package includes up to 50 F-35 Lighting II aircraft, up to 18 MQ-9B Unmanned Aerial Systems and a package of air-to-air and air-to-ground munitions, the State Department said.

The U.S. Senate Foreign Relations and House of Representatives Foreign Affairs committees – whose members have criticized UAE’s role in civilian deaths in Yemen’s civil war – review major weapons sales before the State Department sends its formal notification to the legislative branch.

Any deal the United States makes to sell weapons in the Middle East must satisfy decades of agreement with Israel that it must not impair Israel’s “qualitative military edge” over its neighbors.

The announcement came just days after Democratic challenger Joe Biden won enough states needed to take the presidency from Trump, a Republican who made pro-Israel policies part of his re-election campaign.

Israel initially balked at the prospective sale of F-35 warplanes, valued at $10.4 billion, but dropped its opposition after what it described as U.S. guarantees that Israel’s regional military superiority would be preserved.

The UAE, one of Washington’s closest Middle East allies, has long wanted the stealthy jets and was promised a chance to buy them in a side deal when it agreed to normalize relations with Israel, part of a strategic regional realignment against Iran.

In the past, the F-35 has been denied to Arab states while Israel has about 24 of the jets. Israel is currently slated to purchase 50 of the fighters.

“The proposed sale will make the UAE even more capable and interoperable with U.S. partners in a manner fully consistent with America’s longstanding commitment to ensuring Israel’s Qualitative Military Edge,” Pompeo said.

The $2.97 billon sale of armed drones would mark the first such export since the Trump administration reinterpreted a Cold War-era arms agreement between 34 nations to allow U.S. defense contractors to sell more drones to allies.

(Reporting by Matt Spetalnick and Pete Schroeder; additional reporting by Mike Stone; Editing by David Gregorio and Paul Simao)

Fed’s Kaplan concerned about next six months as virus surges

By Ann Saphir

(Reuters) – Dallas Federal Reserve President Robert Kaplan said on Tuesday he was “cautious and concerned” about downside economic risks in the short run because of the resurgence of the coronavirus, but more optimistic in the longer term.

“The next two quarters are going to be very challenging, very difficult,” Kaplan told Bloomberg’s Future of Finance virtual conference. “Downside risks are growing with this resurgence.”

Still, he said, the U.S. economy will likely rebound strongly in the second half of next year, after a vaccine is widely available, adding that his business contacts have told him they are gearing up for exactly that.

The United States is experiencing a rise in cases, hospitalizations and deaths from COVID-19, with some state and local governments re-imposing restrictions to slow the spread.

With millions of out-of-work Americans dipping into savings built with government aid distributed earlier this year, Kaplan said, household income and spending will drop off “at some point” unless more fiscal aid is forthcoming.

Aid to small businesses in the form of a renewed Paycheck Protection Program would be particularly helpful, he said, because while financial conditions are broadly fairly loose, that is not the case for smaller businesses that rely on banks for credit.

“While we are in the teeth of the pandemic I believe we need to do what we need to do to fight the pandemic,” Kaplan said in a separate event sponsored by UT Dallas.

As long as the pandemic is ongoing, the U.S. central bank should not back away from its programs supporting economic growth, which include bond purchases totaling $120 billion a month and lending programs to corporate America, he said.

Once it subsides, he said, the U.S. will need to moderate government debt.

(Reporting by Ann Saphir; Editing by Paul Simao and Chizu Nomiyama)

Biden camp considers legal action over agency’s delay in recognizing transition

By Simon Lewis and Tim Reid

WILMINGTON, Del. (Reuters) – President-elect Joe Biden’s transition team is considering legal action over a federal agency’s delay in recognizing the Democrat’s victory over President Donald Trump in last week’s election, a Biden official said on Monday.

The General Services Administration (GSA) normally recognizes a presidential candidate when it becomes clear who has won an election so that a transition of power can begin.

That has not yet happened despite U.S. television and news networks declaring Biden the winner on Saturday after he secured enough electoral votes to secure the presidency.

The law does not clearly spell out when the GSA must act, but Biden transition officials say their victory is clear and a delay is not justified, even as Trump refuses to concede defeat.

Trump has repeatedly claimed, without evidence, that there was widespread voting fraud and has filed a raft of lawsuits to challenge the results.

Election officials across the country say there has been no evidence of significant fraud, and legal experts say Trump’s efforts are unlikely to succeed.

GSA Administrator Emily Murphy, appointed by Trump in 2017, has not yet determined that “a winner is clear,” a spokeswoman said. A source close to Murphy said she was a thorough professional who would take her time making a careful decision.

A Biden transition official told reporters on a call that it was time for the GSA’s administration to grant what is known as an ascertainment recognizing the president-elect, and said the transition team would consider legal action if it was not granted.

“Legal action is certainly a possibility, but there are other options as well that we’re considering,” said the official, who spoke on condition of anonymity, declining to outline other options.

The delay is costing the Biden team access to millions of dollars in federal funding and the ability to meet with officials at intelligence agencies and other departments

The transition team needs to be recognized to access funds for salaries, consultants and travel, as well as access to classified information, the official said.

In addition, the team has no access to the State Department, which usually facilitates calls between foreign leaders and the president-elect, the official said.

A senior administration official said the agency did not approve the start of a formal transition process in 2000 for five weeks while Republican George W. Bush and Democrat Al Gore battled over an election that came down to just hundreds of votes in Florida.

(Reporting by Simon Lewis and Tim Reid; Additional reporting by Trevor Hunnicutt and Andrea Shalal; Editing by Kim Coghill and Peter Cooney)

U.S. denounces terms for WHO-led inquiry into COVID origins

By Stephanie Nebehay

GENEVA (Reuters) – The United States, which has accused China of having hidden the extent of its coronavirus outbreak, called on Tuesday for a “transparent and inclusive” WHO-led international investigation into the origin of the pandemic, criticizing its current terms.

The Trump administration has accused the World Health Organization of being “China-centric” and of being its puppet, which WHO director-general Tedros Adhanom Ghebreyesus has denied.

The virus, known as SARS-CoV-2, is believed to have emerged in the Chinese central city of Wuhan late last year, possibly from bats at a market with live animals.

Chinese scientists are carrying out research into its origins and how it jumped the species barrier. A WHO-led international team formed in September is to develop plans for longer-term studies building on China’s findings, according to the WHO’s published terms of reference.

Garrett Grigsby, head of the global affairs office at the U.S. Department of Health and Human Services, told the WHO’s ministerial assembly that member states had been informed of the investigation’s terms of reference only a few days ago.

The terms were “not negotiated in a transparent way with all WHO member states” and “the investigation itself appears to be inconsistent” with its mandate, he said, without elaborating.

“Understanding the origins of COVID-19 through a transparent and inclusive investigation is what must be done to meet the mandate,” Grigsby said.

Britain called for prioritizing the probe, adding: “We expect the investigation and its outcomes to be grounded in robust science.”

Sun Yang, of China’s National Health Commission, did not mention the investigation in his speech on Tuesday, but said that China supports “WHO’s continued leadership role”.

German Health Minister Jens Spahn, speaking for the European Union on Monday, called for “full transparency and cooperation” during all phases of the investigation.

WHO’s top emergency expert Mike Ryan said on Oct. 30 that the WHO-led team and its Chinese counterparts had held a first virtual meeting regarding joint investigations and would deploy on the ground in time.

A separate independent panel said on Tuesday it was working to establish “an accurate and authoritative chronology” behind the first outbreaks and responses. Former New Zealand Prime Minister Helen Clark and former Liberian President Ellen Johnson Sirleaf were named in July to co-lead the WHO panel.

Trump announced a temporary halt to U.S. funding to the WHO in April, prompting condemnation from many world leaders. The United Nations said in July it had received formal notification of the U.S. decision to leave the body next year.

(Reporting by Stephanie Nebehay; Editing by Catherine Evans and Nick Macfie)

Afghan woman shot, blinded, for getting a job

By Abdul Qadir Sediqi

KABUL (Reuters) – The last thing 33-year-old Khatera saw were the three men on a motorcycle who attacked her just after she left her job at a police station in Afghanistan’s central Ghazni province, shooting at her and stabbing her with a knife in the eyes.

Waking up in hospital, everything was dark.

“I asked the doctors, why I can’t see anything? They told me that my eyes are still bandaged because of the wounds. But at that moment, I knew my eyes had been taken from me,” she said.

She and local authorities blame the attack on Taliban militants – who deny involvement – and say the assailants acted on a tip-off from her father who vehemently opposed her working outside the home.

For Khatera, the attack caused not just the loss of her sight but the loss of a dream she had battled to achieve – to have an independent career. She joined the Ghazni police as an officer in its crime branch a few months ago.

“I wish I had served in police at least a year. If this had happened to me after that, it would have been less painful. It happened too soon … I only got to work and live my dream for three months,” she told Reuters.

The attack on Khatera, who only uses one name, is indicative of a growing trend, human rights activists say, of an intense and often violent backlash against women taking jobs, especially in public roles. In Khatera’s case, being a police officer could have also angered the Taliban.

The rights activists believe a mix of Afghanistan’s conservative social norms and an emboldened Taliban gaining influence while the United States withdraws its troops from the country is driving the escalation.

The Taliban are currently negotiating in Doha, Qatar, with the Afghan government to broker a peace deal in which many expect them to formally return to power, but progress is slow and there has been an uptick in fighting and attacks on officials and prominent women around the country.

In recent months, the Taliban have said they will respect women’s rights under Sharia law but many educated women say they have doubts. The insurgent group has opposed a reform to add mother’s names to identity cards, one of the first concrete stances they have revealed on women’s rights as they engage in the peace process.

“Though the situation for Afghan women in public roles has always been perilous, the recent spike in violence across the country has made matters even worse,” said Samira Hamidi, Amnesty International’s Afghanistan campaigner. “The great strides made on women’s rights in Afghanistan over more than a decade must not become a casualty of any peace deal with the Taliban.”

CHILDHOOD DREAM DASHED

Khatera’s dream as a child was to work outside the home and after years of trying to convince her father, to no avail, she was able to find support from her husband.

But her father, she said, did not give up on his opposition.

“Many times, as I went to duty, I saw my father following me … he started contacting the Taliban in the nearby area and asked them to prevent me from going to my job,” she said.

She said that he provided the Taliban with a copy of her ID card to prove she worked for police and that he had called her throughout the day she was attacked, asking for her location.

Ghazni’s police spokesman confirmed they believed the Taliban were behind the attack and that Khatera’s father had been taken into custody. Reuters was unable to reach him directly for comment.

A Taliban spokesman said the group was aware of the case, but that it was a family matter and they were not involved.

Khatera and her family, including five children, are now hiding out in Kabul, where she is recovering and mourning the career she lost.

She struggles to sleep, jumps when she hears a motorbike and has had to cut off contact with her extended family, including her mother, who blame her for her father’s arrest. She hopes desperately that a doctor overseas might somehow be able to partially restore her sight.

“If it is possible, I get back my eyesight, I will resume my job and serve in the police again,” she said, adding in part she needed an income to avoid destitution. “But the main reason is my passion to do a job outside the home.”

(Reporting by Abdul Qadir Sediqi; Additional reporting by Orooj Hakimi and Charlotte Greenfield; Writing by Charlotte Greenfield; Editing by Raju Gopalakrishnan)

U.S. envoy: Lebanon’s Bassil was open to breaking ties with Hezbollah

By Laila Bassam

BEIRUT (Reuters) – The U.S. envoy to Lebanon said on Monday that Lebanese Christian politician Gebran Bassil, who has been sanctioned by the United States, had voiced willingness to sever ties with Hezbollah, challenging his assertion that he rejected the idea outright.

Washington on Friday blacklisted Bassil, son-in-law of Lebanon’s president and leader of its biggest Christian bloc, over charges of corruption and ties with the Iran-backed Shi’ite Hezbollah, which Washington deems a terrorist group.

Bassil slammed the sanctions as unjust and politically motivated, saying they were imposed after he refused to submit to a U.S. demand to break ties with Hezbollah as that would risk Lebanon’s national unity and peace.

U.S. Ambassador Dorothy Shea told Lebanon’s Al Jadeed TV that Bassil, in exchanges with her, had “expressed willingness to break with Hezbollah, on certain conditions.

“He actually expressed gratitude that the United States had gotten him to see how the relationship is disadvantageous to the party,” said Shea, without elaborating on the conditions.

Bassil did not immediately respond to a request for comment.

He, along with an array of the political elite, have been the target of mass protests since October 2019 against widely perceived corruption, waste and mismanagement of state funds.

Bassil denied corruption charges and said he would fight the sanctions in U.S. courts and sue for damages. President Michel Aoun said Lebanon would seek evidence from Washington.

“We endeavor to make as much information publicly available as possible when announcing designations, but, as is often the case, some of this information is not releasable,” said Shea, adding that Bassil was welcome to legally contest the blacklisting.

Bassil was sanctioned under the Global Magnitsky Human Rights Accountability Act, which targets human rights abuses and corruption. Shea did not rule out further sanctions against him or others in Lebanon.

Washington in September blacklisted two former Lebanese government ministers it accused of directing political and economic favors to Hezbollah.

(Reporting by Laila Bassam; Writing by Ghaida Ghantous; Editing by Mark Heinrich)

Biden convenes U.S. pandemic task force, implores Americans to wear masks

By Simon Lewis

WILMINGTON, Del. (Reuters) – U.S. President-elect Joe Biden implored Americans on Monday to wear protective masks to combat the coronavirus pandemic, appealing to their patriotism, as he convened a task force to devise a blueprint for tackling the public health crisis.

“We could save tens of thousands of lives if everyone would just wear a mask for the next few months. Not Democratic or Republican lives. American lives,” Biden told reporters in Wilmington, Delaware. “I implore you. Wear a mask. Do it for yourself. Do it for your neighbor. A mask is not a political statement.”

The pandemic has killed more than 237,000 Americans and thrown millions out of work. Biden spoke two days after clinching election victory over Donald Trump, though the Republican president has not acknowledged defeat and is pursuing legal challenges to the results while making unfounded claims of fraud.

Biden, set to take office on Jan. 20, conferred by video with his 13-member task force, headed by former U.S. Surgeon General Vivek Murthy, former Food and Drug Administration Commissioner David Kessler and Yale University healthcare equity expert Marcella Nunez-Smith.

The president-elect labeled as “great news” Pfizer Inc’s announcement on Monday that its experimental COVID-19 vaccine was more than 90% effective. But Biden said it would be “many more months before there is widespread vaccination” in the United States and underscored the importance of wearing protective masks and social distancing.

The United States has been registering record high infection numbers in recent days. Mask wearing has become a political issue in the United States, with Trump mocking Biden for wearing a mask during the campaign and many conservatives contending masks infringe upon their individual freedom.

“The goal is to get back to normal as fast as possible,” Biden said. “And masks are critical in doing that. It won’t be forever. But that’s how we’ll get our nation back up to speed economically, so we can go back to celebrating birthdays and holidays together, so we can attend sporting events together, so that we can get back to the lives and connections we shared before the pandemic.”

Biden during the campaign accused Trump of panicking and surrendering to the pandemic. Trump promoted unproven medicines, assailed public health experts, failed to signal empathy or compassion as the death toll mounted and disregarded advice on mask wearing and social distancing, ending up hospitalized in October receiving treatments for COVID-19.

Housing Secretary Ben Carson on Monday became the latest close Trump associate to test positive for the virus, his chief of staff said, just days after White House Chief of Staff Mark Meadows also tested positive.

Pfizer and German partner BioNTech SE are the first drugmakers to release successful data from a large-scale clinical trial of a vaccine for the novel coronavirus.

Biden said his team will focus on making rapid COVID-19 testing widely available and building a corps of contact-tracers to track and curb the pathogen’s spread and prioritize vulnerable populations. Biden said his administration would work to get an approved vaccine “distributed as quickly as possible to as many Americans as possible, free of charge.”

The task force will liaise with local and state officials to consider how to safely reopen schools and businesses and tackle racial disparities.

The Biden panel includes Rick Bright, a whistleblower who says he was removed from his Trump administration post for raising concerns about coronavirus preparedness, and Luciana Borio, who specializes in complex public health emergencies.

Vice President Mike Pence is due to meet on Monday with the White House coronavirus task force for the first time since October.

Biden cleared the threshold of 270 Electoral College votes needed to win the presidency on Saturday, four days after the Nov. 3 election. He beat Trump by more than 4.3 million votes nationwide, with Trump becoming the first U.S. president since 1992 to lose a re-election bid.

TRUMP DOES NOT BUDGE

Trump has often attacked the integrity of the U.S. voting process without offering evidence. Some of his allies have encouraged him to exhaust every recourse for hanging onto power. He has filed an array of lawsuits to press his claims and plans rallies to build support for his election challenge, campaign spokesman Tim Murtaugh said.

Asked when Trump would concede or call Biden, Trump campaign adviser Jason Miller on Monday told Fox Business Network: “That word’s not even in our vocabulary now. We’re going to pursue all these legal means, all the recount methods.”

Trump has been talking with his advisers about the possibility of running for president in 2024, a source familiar with the discussions said.

Trump campaign manager Bill Stepien held an all-staff meeting at campaign headquarters on Monday to give the message that Trump is “still in this fight,” a source familiar with the meeting said. The source said the meeting was aimed at bolstering morale given that the last paycheck everyone is to receive is on Nov. 15.

Governments from around the world have congratulated Biden since Saturday, signaling they are turning the page.

Russia, which U.S. intelligence agencies have said interfered in the 2016 election to support Trump and then sought to disparage Biden in this year’s race, said on Monday it would wait for the official results before commenting, noting Trump’s legal challenges. China was similarly cautious.

(Reporting by Andy Sullivan and Andrea Shalal in Washington and Simon Lewis and Trevor Hunnicutt in Wilmington, Delaware; Additional reporting by Jason Lange, Susan Heavey, Doina Chiacu, Makini Brice, Alexandra Alper and Steve Holland in Washington and Costas Pitas in London; Writing by Will Dunham and Andy Sullivan; Editing by Scott Malone, Catherine Evans and Grant McCool)

New U.S. COVID-19 cases up 34% last week, set fresh records

By Michael Erman and Julie Steenhuysen

(Reuters) – Pfizer Inc’s experimental COVID-19 vaccine is more than 90% effective based on initial trial results, the drugmaker said on Monday, a major victory in the war against a virus that has killed over a million people and battered the world’s economy.

Experts welcomed the first successful interim data from a large-scale clinical test as a watershed moment that showed vaccines could help halt the pandemic, although mass roll-outs, which needs regulatory approval, will not happen this year.

Pfizer and German partner BioNTech SE said they had found no serious safety concerns yet and expected to seek U.S. authorization this month for emergency use of the vaccine, raising the chance of a regulatory decision as soon as December.

If granted, the companies estimate they can roll out up to 50 million doses this year, enough to protect 25 million people, and then produce up to 1.3 billion doses in 2021.

“Today is a great day for science and humanity,” said Pfizer Chief Executive Albert Bourla.

“We are reaching this critical milestone in our vaccine development program at a time when the world needs it most with infection rates setting new records, hospitals nearing over-capacity and economies struggling to reopen,” he said.

Experts said they still wanted to see the full trial data, which have yet to be peer-reviewed or published in a medical journal, but the preliminary results looked encouraging.

“This news made me smile from ear to ear. It is a relief to see such positive results on this vaccine and bodes well for COVID-19 vaccines in general,” said Peter Horby, professor of emerging infectious diseases at the University of Oxford.

There are still many questions, such as how effective the vaccine is by ethnicity or age, and how long it will provide immunity, with the “new normal” of social distancing and face covering set to remain for the foreseeable future.

Pfizer expects to seek U.S. emergency use authorization for people aged 16 to 85. To do so, it will need two months of safety data from about half the study’s 44,000 participants, which is expected in the third week of November.

U.S. Health and Human Services Secretary Alex Azar said it would take several weeks for U.S. regulators to receive and process data on the vaccine before the government could potentially approve it.

MARKETS SURGE

The prospect of a vaccine electrified world markets with the S&P 500 and Dow hitting record highs as shares of banks, oil companies and travel companies soared. Shares in companies that have thrived during lockdowns, such as conferencing platform Zoom Video and online retailers, tumbled.

Pfizer shares jumped more than 11% to their highest since July last year, while BioNTech’s stock hit a record high.

Shares of other vaccine developers in the final stage of testing also rose with Johnson & Johnson up 4% and Moderna Inc, whose vaccine uses a similar technology as the Pfizer shot, up 8%. Britain’s AstraZeneca, however, fell 2%. Moderna is expected to report results from its large-scale trial later this month.

“The efficacy data are really impressive. This is better than most of us anticipated,” said William Schaffner, infectious diseases expert at Vanderbilt University School of Medicine in Nashville, Tennessee. “The study isn’t completed yet, but nonetheless the data look very solid.”

U.S. President Donald Trump welcomed the test results, and the market boost: “STOCK MARKET UP BIG, VACCINE COMING SOON. REPORT 90% EFFECTIVE. SUCH GREAT NEWS!” he tweeted.

President-elect Joe Biden said the news was excellent but did not change the fact that face masks, social distancing and other health measures would be needed well into next year.

The World Health Organization said the results were very positive, but warned there was a funding gap of $4.5 billion that could slow access to tests, medicines and vaccines in low- and middle-income countries.

‘NEAR ECSTATIC’

“I’m near ecstatic,” Bill Gruber, one of Pfizer’s top vaccine scientists, said in an interview. “This is a great day for public health and for the potential to get us all out of the circumstances we’re now in.”

Between 55% and 65% of the population will need to be vaccinated to break the dynamic of the spread of COVID-19, said Germany’s health minister Jens Spahn, adding that he did not expect a shot to be available before the first quarter of 2021.

The European Union said on Monday it would soon sign a contract for up to 300 million doses of the Pfizer and BioNTech COVID-19 vaccine.

The companies have a $1.95 billion contract with the U.S. government to deliver 100 million vaccine doses beginning this year. They did not receive research funding from the Trump administration’s Operation Warp Speed vaccine program.

The drugmakers have also reached supply agreements with the United Kingdom, Canada and Japan.

Pfizer said the interim analysis, conducted after 94 participants in the trial developed COVID-19, examined how many had received the vaccine versus a placebo.

Pfizer did not break down how many of those who fell ill received the vaccine. Still, over 90% effectiveness implies that no more than 8 of the 94 had been given the vaccine, which was administered in two shots about three weeks apart.

The efficacy rate, which could drop once full results are available, is well above the 50% effectiveness required by the U.S. Food and Drug Administration for a coronavirus vaccine.

Shortly after Pfizer’s announcement, Russia said its Sputnik V vaccine was also more than 90% effective, based on data collated from inoculations of the public. Its preliminary Phase III trial data is due to be published this month.

MORE DATA NEEDED

To confirm the efficacy rate, Pfizer said it would continue its trial until there were 164 COVID-19 cases among volunteers. Bourla told CNBC on Monday that based on rising infection rates, the trial could be completed before the end of November.

Pfizer said its data would be peer reviewed once it has results from the entire trial.

“These are interesting first signals, but again they are only communicated in press releases,” said Marylyn Addo, head of tropical medicine at the University Medical Center Hamburg-Eppendorf in Germany.

Dozens of drugmakers and research groups around the globe have been racing to develop vaccines against COVID-19, which on Sunday exceeded 50 million cases since the new coronavirus first emerged late last year in China.

The Pfizer and BioNTech vaccine uses messenger RNA (mRNA) technology, which relies on synthetic genes that can be generated and manufactured in weeks, and produced at scale more rapidly than conventional vaccines. The technology is designed to trigger an immune response without using pathogens, such as actual virus particles.

The Trump administration has said it will have enough vaccine doses for all of the 330 million U.S. residents who want it by the middle of 2021.

(Reporting by Michael Erman and Julie Steenhuysen; Additional reporting by Michele Gershberg in New York, Ludwig Burger and Patricia Weiss in Frankfurt and Kate Kelland in London; Editing by Bill Berkrot, Caroline Humer, Edwina Gibbs and David Clarke)

WHO chief looks forward to working ‘very closely’ with Biden team

By Stephanie Nebehay and Emma Farge

GENEVA (Reuters) – The World Health Organization chief welcomed efforts on Monday to strengthen the Geneva-based body through reform and said that it was looking forward to working closely with the administration of U.S. President-elect Joe Biden.

WHO’s funding must become more flexible and predictable to end a “major misalignment” between expectations and available resources, WHO director-general Tedros Adhanom Ghebreyesus said, citing reform efforts by France, Germany and the European Union.

“We still have a lot of work left to do, but we believe that we’re on the right track,” Tedros told health ministers as the annual meeting resumed of the WHO, which groups 194 countries.

U.S. President Donald Trump has frozen U.S. funding to the WHO and begun a process that would see the United States withdraw from the body next July, drawing wide international criticism amid the COVID-19 crisis. He accuses the WHO of being “China-centric” in its handling of the pandemic, which Tedros has repeatedly denied.

Biden, who will convene a national coronavirus task force on Monday, said during campaigning he would rescind Trump’s decision to abandon the WHO on his first day in office.

Tedros urged the international community to recapture a sense of common purpose, adding: “In that spirit we congratulate President-elect Joe Biden and Vice President-elect Kamala Harris and we look forward to working with this administration very closely.

“We need to reimagine leadership, build on mutual trust and mutual accountability to end the pandemic and address the fundamental inequalities that lie at the root of so many of the world’s problems,” he said.

An oversight panel called last week for reforms at the WHO including “predictable and flexible” funding and setting up a multi-tiered system to warn countries earlier about disease outbreaks before they escalate.

Tedros, speaking from quarantine after being in contact with an individual with COVID-19 more than a week ago, began with a minute’s silence, noting that COVID-19 cases approached 50 million with 1.2 million deaths.

Speaking shortly before Pfizer Inc said its experimental COVID-19 vaccine was more than 90% effective, Tedros said vaccines being developed to curb the pandemic should be allocated fairly as “global public goods, not private commodities”.

(Reporting by Stephanie Nebehay and Emma Farge; Editing by Catherine Evans)